An interventional study of Activ-L Artificial Disc and ProDisc-L Total Disc Replacement or Charité Artificial Disc in Degenerative Disc Disease, sponsored by Aesculap Implant Systems. Completed at 17 sites in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-07.
Sponsored by Aesculap Implant Systems · Not applicable, Interventional, and Treatment
The purpose of this study is to learn whether an investigational device called the Activ-L Artificial Disc is safe and effective in the treatment of degenerative disc disease of the lower (lumbar) spine.
The objective of this clinical study is to evaluate the safety and effectiveness of the Activ-L Artificial Disc for treatment of single-level degenerative disc disease of the lumbar spine in patients who have been unresponsive to at least six months of prior conservative care. The hypothesis of the study is that the Activ-L Disc is non-inferior to the control (the Charité® Artificial Disc [DePuy Spine] or ProDisc-L® Total Disc Replacement [Synthes Spine]) with respect to the rate of individual subject success at 24 months. Individual subject success is a composite of effectiveness and safety.
267 studies on the registry are indexed under Spinal Diseases; 54 are open to participants now.
This study's enrollment of 376 is above the median of 52 across 166 interventional studies indexed under Spinal Diseases.
Browse Spinal Diseases studies →Aesculap Implant Systems is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Symptomatic DDD with objective evidence of lumbar DDD, with any of the following characteristics by MRI scan:
Single level symptomatic disease at L4/L5 or L5/S1.
Exclusion Criteria:
Implantation of the Activ-L Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
Device: Activ-L Artificial Disc
Implantation of either the ProDisc-L Total Disc Replacement or Charité Artificial Disc at one level of the lumbar spine, either L4/L5 or L5/S1.
Device: ProDisc-L Total Disc Replacement or Charité Artificial Disc
Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
Overall Success at 24 Months Relative to Baseline
Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement of neurological status; improvement in ODI score.
Time frame: 24 months
Device Success
Percent of subjects demonstrating no Subsequent Surgical Interventions (SSI's) at the index level (L4-L5 or L5-S1) at 24 months.
Time frame: 24 months
Absence of Serious Device Related Adverse Events
Percent of subjects demonstrating no device related SAE's at 24 months as per the Clinical Events Committee (CEC)
Time frame: 24 months
Range of Motion (ROM) Success
Percent of subjects demonstrating maintenance or improvement in ROM at 24 months compared to baseline
Time frame: 24 months
Neurological Success
Percent of patients demonstrating maintenance or improvement in combined motor and sensory evaluations at 24 months compared to baseline
Time frame: 24 months
ODI Success
Percent of subjects demonstrating an improvement of greater than or equal to 15 points at 24 months compared to baseline
Time frame: 24 months
VAS Success for Back and Leg Pain at Rest
Number of patients demonstrating improvement in back and leg pain at 24 months compared to baseline
Time frame: 24 months
ODI Success Using Two Measures of Success
Number of subjects demonstrating improvement in two measures of ODI success at 24 months compared to baseline
Time frame: 24 months
Improvement in SF-36 Scores
Number of subjects demonstrating a greater than or equal to 15% improvement in mental (MCS) and physical (PCS) component summary scores at 24 months compared to baseline
Time frame: 24 months
Subjects were screened and enrolled at 19 US health care center sites
| Milestone | Investigational | Control |
|---|---|---|
| Started | 264 | 112 |
| Baseline | 218 | 106 |
| 24 months | 191 | 89 |
| Completed | 191 | 89 |
| Not completed | 73 | 23 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lost to follow-up | 12 | 9 |
| Withdrew: Physician decision | 8 | 3 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Non-randomized training subjects | 46 | 6 |
Measured by absence of treatment failure; absence or serious device related AE; maintenance or improvement of ROM at index level; maintenance or improvement of neurological status; improvement in ODI score.
| percentage of participants | Investigational | Control |
|---|---|---|
| Including ROM success component | 42.2 (35.6 to 49.1) | 28.3 (20.0 to 37.9) |
| Without ROM success component | 61.9 (55.1 to 68.4) | 52.8 (42.9 to 62.6) |
Number of patients demonstrating improvement in back and leg pain at 24 months compared to baseline
| participants | Investigational | Control |
|---|---|---|
| VAS Rating for Back Pain | 162 | 72 |
| VAS Rating for Left Leg Pain | 72 | 35 |
| VAS Rating for Right Leg Pain | 73 | 36 |
Percent of subjects demonstrating no Subsequent Surgical Interventions (SSI's) at the index level (L4-L5 or L5-S1) at 24 months.
| percentage of participants | Investigational | Control |
|---|---|---|
| Device Success | 84.4 (78.9 to 89.0) | 84.9 (76.6 to 91.1) |
Percent of subjects demonstrating no device related SAE's at 24 months as per the Clinical Events Committee (CEC)
| percentage of participants | Investigational | Control |
|---|---|---|
| Absence of Serious Device Related Adverse Events | 76.6 (70.4 to 82.1) | 70.8 (61.1 to 79.2) |
Percent of subjects demonstrating maintenance or improvement in ROM at 24 months compared to baseline
| percentage of participants | Investigational | Control |
|---|---|---|
| Range of Motion (ROM) Success | 58.7 (51.9 to 65.3) | 42.5 (32.9 to 52.4) |
Percent of patients demonstrating maintenance or improvement in combined motor and sensory evaluations at 24 months compared to baseline
| percentage of participants | Investigational | Control |
|---|---|---|
| Neurological Success | 80.3 (74.4 to 85.3) | 76.4 (67.2 to 84.1) |
Percent of subjects demonstrating an improvement of greater than or equal to 15 points at 24 months compared to baseline
| percentage of participants | Investigational | Control |
|---|---|---|
| ODI Success | 75.2 (68.9 to 80.8) | 66.0 (56.2 to 75.0) |
Number of subjects demonstrating improvement in two measures of ODI success at 24 months compared to baseline
| participants | Investigational | Control |
|---|---|---|
| Greater than or equal to 15 points of improvement | 164 | 70 |
| Greater than or equal to 15% improvement | 170 | 77 |
Number of subjects demonstrating a greater than or equal to 15% improvement in mental (MCS) and physical (PCS) component summary scores at 24 months compared to baseline
| participants | Investigational | Control |
|---|---|---|
| SF-36 MCS | 101 | 48 |
| SF-36 PCS | 156 | 69 |
Collected over Serious and Non-Serious Adverse Events Adjudicated as of 9 October 2015. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Investigational | — | 86/218 (39.4%) | 197/218 (90.4%) |
| Control | — | 57/106 (53.8%) | 100/106 (94.3%) |
| Event | Investigational | Control |
|---|---|---|
| Lumbar and Lower Extremity PainNervous system disorders | 9/218 | 8/106 |
| Non-Lumbar Radiographic ObservationMusculoskeletal and connective tissue disorders | 2/218 | 6/106 |
| Lumbar Only PainNervous system disorders | 6/218 | 6/106 |
| CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 11/218 | 5/106 |
| Intestinal IssuesGastrointestinal disorders | 5/218 | 5/106 |
| Joint or Muscle IssuesMusculoskeletal and connective tissue disorders | 10/218 | 0/106 |
| Pain in Non-Lumbar or LegMusculoskeletal and connective tissue disorders | 3/218 | 4/106 |
| Lower Extremity PainNervous system disorders | 7/218 | 4/106 |
| Non-Lumbar and Lower Extremities DeficitNervous system disorders | 3/218 | 4/106 |
| Male Reproductive System IssuesReproductive system and breast disorders | 5/218 | 4/106 |
| Event | Investigational | Control |
|---|---|---|
| Lumbar Only PainNervous system disorders | 44/218 | 30/106 |
| Lumbar and Lower Extremity PainNervous system disorders | 42/218 | 23/106 |
| Pain in Non-Lumbar or LegMusculoskeletal and connective tissue disorders | 45/218 | 14/106 |
| TraumaInjury, poisoning and procedural complications | 38/218 | 21/106 |
| Lower Extremity PainNervous system disorders | 40/218 | 11/106 |
| Lumbar and Lower Extremity Sensory DeficitMusculoskeletal and connective tissue disorders | 24/218 | 16/106 |
| Gastric IssuesGastrointestinal disorders | 27/218 | 9/106 |
| Index Procedure Related WoundsSurgical and medical procedures | 17/218 | 12/106 |
| Urinary IssuesRenal and urinary disorders | 23/218 | 7/106 |
| Intestinal IssuesGastrointestinal disorders | 16/218 | 11/106 |
All enrolled subjects
| Age, Categorical(Participants) | Investigational | Control | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 264 | 112 | 376 |
| >=65 years | 0 | 0 | 0 |
| Age, Continuous(years) | Investigational | Control | Total |
|---|---|---|---|
| Mean | 39.1 ± 8.6 | 40.0 ± 8.6 | 39.6 ± 8.6 |
| Sex: Female, Male(Participants) | Investigational | Control | Total |
|---|---|---|---|
| Female | 124 | 56 | 180 |
| Male | 140 | 56 | 196 |
| Ethnicity (NIH/OMB)(Participants) | Investigational | Control | Total |
|---|---|---|---|
| Hispanic or Latino | 29 | 12 | 41 |
| Not Hispanic or Latino | 235 | 100 | 335 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Investigational | Control | Total |
|---|---|---|---|
| American Indian or Alaska Native | 3 | 0 | 3 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 18 | 5 | 23 |
| White | 233 | 106 | 339 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 1 | 8 |
| Oswestry Disability Index (ODI) Scores for Low Back Pain(units on a scale) | Investigational | Control | Total |
|---|---|---|---|
| Mean | 57.1 ± 13.9 | 58.6 ± 14.1 | 57.9 ± 13.9 |
| Visual Analog Scale (VAS) Ratings for Back and Leg Pain(units on a scale) | Investigational | Control | Total |
|---|---|---|---|
| VAS Back Pain | 79.0 ± 14.9 | 79.1 ± 14.8 | 79.1 ± 14.8 |
| VAS Right Leg Pain | 28.7 ± 29.8 | 32.9 ± 29.6 | 30.6 ± 30.0 |
| VAS Left Leg Pain | 29.6 ± 29.4 | 30.7 ± 29.5 | 30.4 ± 29.6 |
| Short-Form (36) Health Questionnaire (SF-36) Scores(units on a scale) | Investigational | Control | Total |
|---|---|---|---|
| SF-36 MCS | 39.1 ± 13.9 | 39.6 ± 14.9 | 39.4 ± 14.4 |
| SF-36 PCS | 29.9 ± 6.2 | 28.4 ± 6.2 | 29.2 ± 6.2 |
3 further baseline measures are reported on the registry.
Plan to share: No
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Aesculap Implant Systems